IMMUTEP LIMITED - AMER

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

16 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

Immutep to Participate in the JMP Securities Life Sciences Conference

09 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

02 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

01 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

27 4 2023 08:00:02 提供 Nasdaq GlobeNewswire

Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

26 4 2023 10:00:00 提供 Nasdaq GlobeNewswire

Immutep Appoints Dr. Florian Vogl as Chief Medical Officer

26 4 2023 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

17 4 2023 09:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

31 3 2023 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer

30 3 2023 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

23 3 2023 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

14 3 2023 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

06 2 2023 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

30 1 2023 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

04 1 2023 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

23 12 2022 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

08 12 2022 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

06 12 2022 08:00:01 提供 Nasdaq GlobeNewswire

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

02 12 2022 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

29 11 2022 08:00:01 提供 Nasdaq GlobeNewswire